Skip to main content
NACFC 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Livestreamed Session
Livestreamed Session

PHARM
Session Type: Workshop

W25--What Does This Button Do? - Innovations in CF Pharmacotherapy

Friday, October 24, 2025
10:15 AM - 12:15 PM PDT
Location:Signature Room

This workshop will delve into recent advancements and challenges in the treatment and management of cystic fibrosis (CF). Through a series of abstracts, we will explore the gaps in treatment for type 2 inflammation, the financial and administrative impacts the pharmaceutical industry has on CF care, the role of pharmacogenomics in people with CF (pwCF), and the pharmacokinetics of CFTR modulators in pwCF. Attendees will gain insights into the latest research findings and practical applications to improve patient outcomes.

Learning Objectives:

  • Understand the current practice patterns and variations in the use of biologic therapy for type 2 inflammation in people with cystic fibrosis (pwCF).
  • Assess the administrative burden and financial implications of changes in pharmaceutical distribution networks on CF care teams and patients.
  • Analyze the impact of precision medicine, including pharmacogenomic profiling and pharmacokinetics, on medication management in pwCF.

Presentations:

  • 10:15 AM - 12:15 PM PDT
    W25.1- National survey of treatment gaps in type 2 inflammation and cystic fibrosis

    Speaker: Blair Lenhan, MD – University of Utah

  • 10:15 AM - 12:15 PM PDT
    W25.2- Financial & administrative impacts on people with cystic fibrosis, pharmacists, and pharmacy technicians at CFF-accredited care centers following changes in pharmaceutical limited distribution network

    Speaker: Brittany A. Wright, PharmD, BCACP – University of California San Diego

  • 10:15 AM - 12:15 PM PDT
    W25.3- Impact of pharmacogenomic profiling on medication use in pediatric patients with cystic fibrosis

    Speaker: Robyn D. Palmer, PharmD – UNC Health

  • 10:15 AM - 12:15 PM PDT
    W25.4- Physiologically based pharmacokinetic of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis: extrapolation of the dosing regimen in children under 2 years of age

    Speaker: Ngoc Hoa Truong, n/a – URP7323, Pharmacologie Et Évaluation Des Thérapeutiques Chez L'enfant Et La Femme Enceinte Université Paris Cité, Paris, France.

  • 10:15 AM - 12:15 PM PDT
    W25.5- Modeling a single variable-time measurement of Elexacaftor/Tezacaftor/Ivacaftor in adults

    Speaker: Silvia Caceres, MS – University of North Carolina- Chapel Hill/ National Jewish Health